Iterum Therapeutics plc (ITRM) Revenue History
Annual and quarterly revenue from 2016 to present
ITRM Revenue Over Time (2016–2024)
ITRM Revenue Growth History
1 of 3 years with positive growth- FY2016 revenue growth
- N/A
- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- +71.1%
- FY2019 revenue growth
- -95.7%
- FY2020 revenue growth
- -100.0%
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2025 | $390K | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
| Q1 2024 | $0 | — |
| Q4 2023 | $0 | — |
Multi-year avg. share of annual revenue by fiscal quarter
ITRM Revenue Analysis (2016–2024)
Current Revenue & Growth
As of June 29, 2026, Iterum Therapeutics plc (ITRM) generated trailing twelve-month (TTM) revenue of $390,000. The most recent quarter (Q3 2025) recorded $390,000 in revenue
Historical Growth Trajectory
ITRM's historical revenue data shows various trends over time. Iterum Therapeutics plc's highest annual revenue of $869,000 was recorded in 2018.
Peer Comparison
Compared to Healthcare sector peers — including NKTR (-36.2% YoY), SPRO (+22.8% YoY), and VNDA (+8.2% YoY). Compare ITRM vs NKTR →
ITRM Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ITRMCurrent | $390,000 | - | - | - | |
 NKTR | $55M | -36.2% | -18.4% | -236.8% | |
 SPRO | $60M | +22.8% | +44.9% | -0.0% | |
 VNDA | $216M | +8.2% | -2.7% | -70.0% |
ITRM Historical Revenue Data (2016–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | - | $-254,000 | - | $-18,696,000 | - |
| 2023 | $0 | - | $-1,750,000 | - | $-47,468,000 | - |
| 2022 | $0 | - | $-1,800,000 | - | $-30,383,000 | - |
| 2021 | $0 | - | $-2,104,000 | - | $-24,537,000 | - |
| 2020 | $0 | -100.0% | $-161,000 | - | $-32,126,000 | - |
| 2019 | $37K | -95.7% | $37K | 100.0% | $-102,021,000 | -275732.4% |
| 2018 | $869K | +71.1% | $869K | 100.0% | $-76,559,000 | -8810.0% |
| 2017 | $508K | - | $508K | 100.0% | $-29,455,000 | -5798.2% |
| 2016 | $0 | - | $0 | - | $-13,359,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ITRM — Frequently Asked Questions
Quick answers to the most common questions about buying ITRM stock.
Is ITRM's revenue growth accelerating or slowing?
ITRM TTM revenue: $390000.00. YoY growth: N/A. 5-year CAGR: N/A.
What is ITRM's revenue history from 2016 to 2026?
Iterum Therapeutics plc (ITRM) revenue history spans 2016 to 2026. TTM revenue as of 2026 is $390000.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is ITRM's long-term revenue growth rate (CAGR)?
Iterum Therapeutics plc's 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for ITRM.
Why does ITRM's quarterly revenue fluctuate?
ITRM quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Iterum Therapeutics plc's revenue data from 2016 to 2026 shows full historical quarterly detail on this page.
How is ITRM's revenue distributed by segment?
ITRM reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does ITRM's revenue compare to industry peers?
Iterum Therapeutics plc (ITRM) with TTM revenue of $390000.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.